Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Check ClinicalTrials.gov for specific trial criteria
Glucagon-like peptide-1 (GLP-1) agonists, employed to treat diabetes and obesity, has been tested on MASH patients and is widely regarded as the preferred treatment for MASH
By 2030, households with GLP-1 users are projected to represent 35% of all food and beverage units sold, the consumer packaged goods (CPG) market researcher projected
Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA et al
It may also cover only one medicine
That result sparked a near-5% increase in Roche's share price, and the latest announcement had a similar effect, with the stock up just over 5% at the time of writing
US$ 27.36
US$ 28.43
US$ 27.05
US$ 25.34
US$ 23.68
